Analysts forecast that Avrobio Inc (NASDAQ:AVRO) will post ($0.71) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Avrobio’s earnings, with estimates ranging from ($0.76) to ($0.58). The business is expected to report its next earnings results on Monday, June 24th.
On average, analysts expect that Avrobio will report full year earnings of ($2.77) per share for the current financial year, with EPS estimates ranging from ($3.31) to ($1.86). For the next year, analysts anticipate that the business will post earnings of ($3.00) per share, with EPS estimates ranging from ($3.56) to ($2.14). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Avrobio.
Avrobio (NASDAQ:AVRO) last announced its quarterly earnings results on Monday, March 25th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.10).
Avrobio stock traded up $0.48 during trading hours on Friday, reaching $19.01. The stock had a trading volume of 136,458 shares, compared to its average volume of 121,534. The firm has a market cap of $458.10 million and a PE ratio of -5.25. Avrobio has a 52 week low of $11.85 and a 52 week high of $53.70.
In other news, Director Christopher Paige sold 10,000 shares of Avrobio stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $25.72, for a total transaction of $257,200.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Geoffrey Mackay sold 14,000 shares of Avrobio stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $27.25, for a total transaction of $381,500.00. The disclosure for this sale can be found here.
Several institutional investors and hedge funds have recently made changes to their positions in AVRO. Aisling Capital Management LP bought a new stake in shares of Avrobio during the 4th quarter valued at about $12,271,000. BlackRock Inc. boosted its stake in shares of Avrobio by 4,239.1% during the 3rd quarter. BlackRock Inc. now owns 375,941 shares of the company’s stock valued at $19,500,000 after purchasing an additional 367,277 shares in the last quarter. Emerald Advisers LLC boosted its stake in shares of Avrobio by 61.4% during the 1st quarter. Emerald Advisers LLC now owns 614,408 shares of the company’s stock valued at $13,548,000 after purchasing an additional 233,772 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Avrobio by 65.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 537,322 shares of the company’s stock valued at $27,871,000 after purchasing an additional 211,847 shares in the last quarter. Finally, Vanguard Group Inc boosted its stake in shares of Avrobio by 374.5% during the 3rd quarter. Vanguard Group Inc now owns 246,738 shares of the company’s stock valued at $12,798,000 after purchasing an additional 194,738 shares in the last quarter. 69.15% of the stock is currently owned by hedge funds and other institutional investors.
Avrobio Company Profile
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Featured Story: Is it Safe to Invest in Commodities?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.